COVID-19 and sickle cell disease.
Published in Haematologica
Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory di...
...Published in Haematologica
From weakly adhesive to highly thrombogenic: the shear gradient switch
Published in Haematologica
ARQ531: the therapy that targets multiple pathways in acute myeloid leukemia
Published in Haematologica
Elevated TWIST1 expression in myelodysplastic syndromes/ acute myeloid leukemia reduces efficacy of hypomethylating ther...
...Published in Haematologica
Dietary intake of heme iron is associated with ferritin and hemoglobin levels in Dutch blood donors: results from Donor ...
...Published in Haematologica
Whole blood donors, especially frequently donating donors, have a risk of iron deficiency and low hemoglobin levels, which may affect their health and eligibility to donate. Lifestyle behaviors, such as dietary iron intake and physical activity, may influence iron stores and thereby hemoglobin levels. We aimed to investigate whether dietary iron in...
The molecular basis for the prothrombotic state in sickle cell disease
Published in Haematologica
The genetic and molecular basis of sickle cell disease (SCD) has long been characterized but the pathophysiological basis has not been entirely defined. How a red cell hemolytic disorder initiates inflammation, endothelial dysfunction, coagulation activation, and eventually leads to vascular thrombosis, is yet to be elucidated. Recent evidence has ...
The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumo...
...Published in Haematologica
Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated for example by the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, for treatment of various blood cancers. Here, we characterize a new multiple kinase ...
Dominant negative Gfi1b mutations cause moderate thrombocytopenia and an impaired stress thrombopoiesis associated with ...
Published in Haematologica
GFI1B -related thrombocytopenia ( GFI1B -RT) is a rare bleeding disorder mainly caused by the presence of truncated GFI1B proteins with dominant-negative properties. The disease is characterized by low platelet counts, the presence of abnormal platelets, a megakaryocytic expansion, and mild erythroid defects. However, there are no animal models tha...
Thromboinflammatory mechanisms in sickle cell disease – challenging the hemostatic balance
Published in Haematologica
Sickle cell disease (SCD) is an inherited hemoglobinopathy that is caused by the presence of abnormal hemoglobin S (HbS) in red blood cells, leading to alterations in red cell properties and shape, as the result of HbS dexoygenation and subsequent polymerization. The pathophysiology of SCD is characterized by chronic inflammatory processes, trigger...
